Search results
How AbbVie denied Americans access to fair competition for Humira
Quartz via Yahoo Finance· 1 year agoHumira, a monoclonal antibody used to treat arthritis among other conditions, is the most lucrative...
What You Need to Know About Humira's Low-Cost Competitors
Verywell Health via Yahoo News· 8 months agoAt least nine Humira biosimilars are coming to market, along with promises of lower costs for...
AbbVie's Botox, dermal fillers face slowdown jitters
Reuters via Yahoo Finance· 2 years ago(Reuters) -Demand for AbbVie Inc's Botox anti-wrinkle injection and the popular facial filler Juvederm would be hit well into the next year by inflation...
2 High-Yield Healthcare Stocks to Buy With Both Hands and 1 to Avoid for Now
Motley Fool via Yahoo Finance· 3 months agoThere's one constant you can always rely on. Regardless of what's happening to the overall economy,...
Which Stock Is More Likely to Double Your Money First: Moderna or AbbVie?
Motley Fool· 2 years agoTake the case of AbbVie (NYSE: ABBV) and Moderna (NASDAQ: MRNA). AbbVie spun off from Abbott...
Is AbbVie Still a Good Dividend Stock to Buy?
Motley Fool· 6 months agoUnfortunately for shareholders of AbbVie (NYSE: ABBV), the drugmaker's top-selling product, Humira, lost patent-protected market exclusivity in the U.S....
Is AbbVie a Good Dividend Stock to Buy on the Dip?
Motley Fool· 1 year agoThe week that ended Jan. 13 was a relatively good one for the stock market overall. Is AbbVie's recent dip the first of many, or could it be an...
2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade
Motley Fool via Yahoo Finance· 4 months agoNow that 2023 is firmly in the rearview, we can say without a doubt that it was a remarkable year...
US patients can spend more than $3,000 per pen for the exact same life-changing arthritis drugs that...
INSIDER via Yahoo News· 1 year agoPriti Krishtel, a "genius" lawyer leading the movement against patent thickets, said people...
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
Reuters via Yahoo Finance· 3 months ago(Reuters) -AbbVie on Friday raised its 2027 forecast for sales of its immunology drugs Skyrizi and...
